 |
市場調查報告書
商品編碼
1618223
2024 - 2032 年非動物替代測試市場機會、成長動力、產業趨勢分析與預測Non-animal Alternative Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
全球非動物替代測試市場在 2023 年價值 18 億美元，預計 2024 年至 2032 年複合年成長率為 11.9%。圍繞動物測試的道德擔憂加劇，加上美國食品和藥物管理局和歐盟等機構的監管舉措，加速了向人道測試替代方案的轉變。這些政策促進對創新技術的投資，提供可行的、合乎道德的測試解決方案。近年來，技術進步使研究人員能夠比傳統的動物測試方法更準確地模擬人類生理反應。
這些創新改變了藥物開發和安全測試，為人類生物學提供了預測性見解。此市場按產品類型分類，包括器官晶片、細胞系和組織模型。細胞系在 2023 年成為主導細分市場，市場價值達 12 億美元。這些模型由於其模仿各種人體生理功能的適應性，在藥效和毒性測試等領域變得非常有價值。
它們的大批量生產能力也使其成為高通量篩選過程的首選，確保獲得監管和科學驗證所必需的一致、可重複的結果。依技術分類，非動物替代測試市場分為細胞培養技術、高通量技術、分子成像和組學。細胞培養技術在 2023 年引領市場，佔據 49.4% 的佔有率，因為它能夠在體外培養和操縱人體細胞，為研究疾病和藥物反應提供更相關的生物模型。該技術不僅提高了測試結果的可靠性，還支持細胞系的可擴展生產，簡化了對藥物發現至關重要的大量化合物的測試。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 18億美元 |
| 預測值 | 48億美元 |
| 複合年成長率 | 11.9% |
由於公眾意識較高以及對動物測試的道德擔憂日益增加，美國非動物替代測試市場預計到 2032 年將達到 19 億美元。 2023年，美國在北美地區收入比重最大，總計6.566億美元。公眾對人道研究實踐的需求促使製藥公司在雄厚的資金和研究補助金（包括美國國立衛生研究院 (NIH) 的捐款）的支持下採用非動物測試。這些資金的湧入正在推動跨部門非動物測試方法的研究和應用，支持從動物模型的永續過渡。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 藥物開發的技術進步
- 不斷增加用於開發替代技術的投資和研究補助金
- 擴大禁止使用動物模型進行研究
- 產業陷阱與挑戰
- 與安全性、有效性和品質相關的嚴格法規
- 成長動力
- 成長潛力分析
- 監管環境
- 美國
- 歐洲
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者細胞株競爭分析
- 主要市場參與者衛生紙生產線的競爭分析
- 器官晶片主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
- 戰略展望矩陣
第 5 章：市場估計與預測：按產品類型，2021 - 2032
- 主要趨勢
- 器官晶片
- 細胞系
- 組織線
第 6 章：市場估計與預測：依方法，2021 - 2032
- 主要趨勢
- 離體測試
- 電腦建模
- 細胞測定
- 生化檢測
第 7 章：市場估計與預測：按技術分類，2021 - 2032
- 主要趨勢
- 細胞培養技術
- 高通量技術
- 分子影像技術
- 組學技術
第 8 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 傳染病
- 免疫疾病
- 腫瘤學
- 心血管疾病
- 糖尿病
- 遺傳疾病
- 神經系統疾病
第 9 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 製藥公司
- 生技公司
- 研究機構與學者
- 合約研究組織
- 其他最終用途
第 10 章：市場估計與預測：按地區分類，2021 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 中東和非洲
- 南非
- 沙烏地阿拉伯
第 11 章：公司簡介
- AlveoliX
- BICO GROUP
- CN Bio Innovations
- Emulate
- Hesperos
- InSphero
- Lonza Group
- Merck
- MIMETAS
- Thermo Fisher Scientific
- TissUse
- VITROCELL Systems
The Global Non-Animal Alternative Testing Market, valued at USD 1.8 billion in 2023, is projected to expand at a CAGR of 11.9% from 2024 to 2032. This growth is driven by rising investments and research grants advancing alternative testing methods. Heightened ethical concerns surrounding animal testing, alongside regulatory initiatives from agencies such as the U.S. FDA and European Union, have accelerated the shift toward humane testing alternatives. These policies foster investment in innovative technologies that offer viable, ethical testing solutions. In recent years, technological advancements have allowed researchers to simulate human physiological responses with more accuracy than traditional animal testing methods.
These innovations transform drug development and safety testing, providing predictive insights into human biology. The market, categorized by product type, includes organ-on-chips, cell lines, and tissue models. Cell lines emerged as the leading segment in 2023, capturing a market value of USD 1.2 billion. These models have become invaluable in fields like drug efficacy and toxicity testing due to their adaptability in mimicking various human physiological functions.
Their capability for high-volume production also makes them a preferred choice for high throughput screening processes, ensuring consistent, reproducible results essential for regulatory and scientific validation. By technology, the non-animal alternative testing market segments into cell culture technology, high-throughput technology, molecular imaging, and omics. Cell culture technology led the market in 2023, with a 49.4% share, due to its capacity to grow and manipulate human cells in vitro, offering a more relevant biological model for studying diseases and drug responses. This technology not only enhances the reliability of test outcomes but also supports the scalable production of cell lines, streamlining the testing of vast numbers of compounds essential for drug discovery.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $1.8 Billion |
| Forecast Value | $4.8 Billion |
| CAGR | 11.9% |
U.S. non-animal alternative testing market is expected to reach USD 1.9 billion by 2032, led by high public awareness and mounting ethical concerns over animal testing. In 2023, the U.S. accounted for the largest revenue share in North America, totaling USD 656.6 million. Public demand for humane research practices has prompted pharmaceutical companies to adopt non-animal testing, backed by robust funding and research grants, including contributions from the National Institutes of Health (NIH). This influx of funding is fueling both research and application of non-animal testing methods across sectors, supporting a sustainable transition away from animal-based models.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Technological advances in drug development
- 3.2.1.2 Growing investments and research grants for developing alternative technologies
- 3.2.1.3 Increasing ban on using animal models for research purposes
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulations related to safety, efficacy and quality
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players cell line
- 4.4 Competitive analysis of major market players tissue line
- 4.5 Competitive analysis of major market players organ-on-chips
- 4.6 Competitive positioning matrix
- 4.7 Strategy dashboard
- 4.8 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Organ-on-chips
- 5.3 Cell lines
- 5.4 Tissue lines
Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Ex vivo testing
- 6.3 Computer modelling
- 6.4 Cellular assay
- 6.5 Biochemical assay
Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Cell culture technology
- 7.3 High throughput technology
- 7.4 Molecular imaging technology
- 7.5 Omics technology
Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Infectious diseases
- 8.3 Immunological diseases
- 8.4 Oncology
- 8.5 Cardiovascular diseases
- 8.6 Diabetes
- 8.7 Genetic diseases
- 8.8 Neurological diseases
Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Pharmaceutical companies
- 9.3 Biotechnological companies
- 9.4 Research institutes and academics
- 9.5 CROs
- 9.6 Other End Use
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
Chapter 11 Company Profiles
- 11.1 AlveoliX
- 11.2 BICO GROUP
- 11.3 CN Bio Innovations
- 11.4 Emulate
- 11.5 Hesperos
- 11.6 InSphero
- 11.7 Lonza Group
- 11.8 Merck
- 11.9 MIMETAS
- 11.10 Thermo Fisher Scientific
- 11.11 TissUse
- 11.12 VITROCELL Systems
